Problems associated with the clinical use of proton pump inhibitors

Pharmacology and Toxicology

Volumn 89, Issue 6, 2001, Pages 281-286

  Gillen, Derek ^a   McColl, Kenneth E L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ATROPHIC GASTRITIS; CARCINOID; DRUG TOLERANCE; ERADICATION THERAPY; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RAT; REBOUND; RISK BENEFIT ANALYSIS; SHORT SURVEY; STOMACH ACID SECRETION; STOMACH CARCINOMA;

HELICOBACTER; HELICOBACTER PYLORI; NEGIBACTERIA; RODENTIA;

EID: 0035654604     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.d01-161.x     Document Type: Short Survey

References (3)

1. Bell, N., K. Rohss, C. Cederberg & R. Hunt: Does tachyphylaxis and/or rebound acid secretion occur during/after treatment with omeprazole or ranitidine. Gastroenterology 1993, 104, A41 (abstract).
2. Bell, N. J. V, D. Burget, C. W. Howden, ?. Wilkinson & R. H. Hunt: Approriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992, 51 (suppl. 1), 59-67.
3. Borch, K., H. Renvall & G. Liedberg: Gastric endocrine cell hyperplasia and carcinoid tumours in pernicious anaemia. Gastroenterology 1985, 88, 638-648.